000650 仁和药业
已收盘 12-23 15:00:00
资讯
新帖
简况
12月13日仁和药业现1笔大宗交易 机构净买入202.01万元
证券之星 · 12-13
12月13日仁和药业现1笔大宗交易 机构净买入202.01万元
仁和药业获全国首批中药经典名方“二冬汤颗粒”
证券之星 · 11-11
仁和药业获全国首批中药经典名方“二冬汤颗粒”
仁和药业最新公告：子公司获得二冬汤颗粒药品注册证书
证券之星 · 11-11
仁和药业最新公告：子公司获得二冬汤颗粒药品注册证书
仁和药业(000650.SZ)子公司获二冬汤颗粒药品注册证书
智通财经 · 11-11
仁和药业(000650.SZ)子公司获二冬汤颗粒药品注册证书
仁和药业：子公司铝碳酸镁咀嚼片通过仿制药质量和疗效一致性评价
中国财富通 · 11-08
仁和药业：子公司铝碳酸镁咀嚼片通过仿制药质量和疗效一致性评价
仁和药业(000650.SZ)：铝碳酸镁咀嚼片通过仿制药质量和疗效一致性评价
智通财经 · 11-08
仁和药业(000650.SZ)：铝碳酸镁咀嚼片通过仿制药质量和疗效一致性评价
仁和药业：铝碳酸镁咀嚼片通过仿制药质量和疗效一致性评价
美港电讯 · 11-08
仁和药业：铝碳酸镁咀嚼片通过仿制药质量和疗效一致性评价
仁和药业(000650)10月31日股东户数11万户，较上期增加10%
证券之星 · 11-04
仁和药业(000650)10月31日股东户数11万户，较上期增加10%
仁和药业（000650）2024年三季报简析：净利润减23.08%，盈利能力上升
证券之星 · 10-30
仁和药业（000650）2024年三季报简析：净利润减23.08%，盈利能力上升
仁和药业(000650)10月10日股东户数10万户，较上期减少2.55%
证券之星 · 10-29
仁和药业(000650)10月10日股东户数10万户，较上期减少2.55%
财报透视｜业绩双降！仁和药业三季度净利大幅下滑57.3%，销售费用是研发投入的15倍
读创财经 · 10-28
财报透视｜业绩双降！仁和药业三季度净利大幅下滑57.3%，销售费用是研发投入的15倍
仁和药业(000650.SZ)发布前三季度业绩，净利润4.16亿元，同比下降23.08%
智通财经 · 10-28
仁和药业(000650.SZ)发布前三季度业绩，净利润4.16亿元，同比下降23.08%
图解仁和药业三季报：第三季度单季净利润同比减57.30%
证券之星 · 10-28
图解仁和药业三季报：第三季度单季净利润同比减57.30%
10月9日仁和药业跌7.23%，广发稳健回报混合A基金重仓该股
证券之星 · 10-09
10月9日仁和药业跌7.23%，广发稳健回报混合A基金重仓该股
仁和药业最新公告：全资子公司获得他达拉非片药品批件
证券之星 · 09-24
仁和药业最新公告：全资子公司获得他达拉非片药品批件
仁和药业（000650）9月10日主力资金净卖出532.67万元
证券之星 · 09-11
仁和药业（000650）9月10日主力资金净卖出532.67万元
仁和药业：公司2023年12月至2024年3月已使用自有资金1亿元进行回购，本次回购已完成
证券之星 · 08-31
仁和药业：公司2023年12月至2024年3月已使用自有资金1亿元进行回购，本次回购已完成
仁和药业(000650)7月19日股东户数9.9万户，较上期增加1.02%
证券之星 · 08-27
仁和药业(000650)7月19日股东户数9.9万户，较上期增加1.02%
仁和药业最新公告：上半年净利润同比下降5.43%
证券之星 · 08-27
仁和药业最新公告：上半年净利润同比下降5.43%
仁和药业(000650.SZ)发布上半年业绩，净利润3.37亿元，下降5.43%
智通财经 · 08-27
仁和药业(000650.SZ)发布上半年业绩，净利润3.37亿元，下降5.43%
加载更多
公司概况
公司名称：
仁和药业股份有限公司
所属行业：
医药制造业
上市日期：
1996-12-10
主营业务：
仁和药业股份有限公司主营业务是生产、销售中西药、原料药及健康相关产品。公司主营产品为口服固体制剂、口服液体制剂、大容量注射剂、小容量注射剂、外用洗剂、搽剂、栓剂、软膏剂等剂型药品以及健康相关产品。公司是全国通过GMP认证生产线最多的企业之一。
发行价格：
6.26
{"stockData":{"symbol":"000650","market":"SZ","secType":"STK","nameCN":"仁和药业","latestPrice":5.83,"timestamp":1734937392000,"preClose":5.95,"halted":0,"volume":25251053,"delay":0,"floatShares":1331000000,"shares":1400000000,"eps":0.3162,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.12,"latestTime":"12-23 15:00:00","open":5.94,"high":5.96,"low":5.83,"amount":148000000,"amplitude":0.0218,"askPrice":5.84,"askSize":752,"bidPrice":5.83,"bidSize":2082,"shortable":0,"etf":0,"ttmEps":0.3162,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1735003800000},"adr":0,"adjPreClose":5.95,"symbolType":"stock","openAndCloseTimeList":[[1734917400000,1734924600000],[1734930000000,1734937200000]],"highLimit":6.55,"lowLimit":5.36,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1399938234,"pbRate":1.37,"roa":"--","roe":"6.79%","epsLYR":0.41,"committee":0.449227,"marketValue":8162000000,"floatMarketCap":7762000000,"peRate":18.437698,"changeRate":-0.0202,"turnoverRate":0.019,"status":1},"requestUrl":"/m/hq/s/000650","defaultTab":"news","newsList":[{"id":"2491734654","title":"12月13日仁和药业现1笔大宗交易 机构净买入202.01万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2491734654","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491734654?lang=zh_cn&edition=full","pubTime":"2024-12-13 16:49","pubTimestamp":1734079764,"startTime":"0","endTime":"0","summary":"证券之星消息，12月13日仁和药业发生大宗交易，交易数据如下：大宗交易成交价格6.03元，成交33.5万股，成交金额202.01万元，买方营业部为机构专用，卖方营业部为中信证券股份有限公司上海分公司。近三个月该股共发生1笔大宗交易，合计成交3350.0手。该股近期无解禁股上市。截至2024年12月13日收盘，仁和药业(000650)报收于6.03元，下跌2.11%，换手率3.02%，成交量40.25万手，成交额2.45亿元。该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121300028947.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650","BK0097","BK0188","BK0239"],"gpt_icon":0},{"id":"2482391783","title":"仁和药业获全国首批中药经典名方“二冬汤颗粒”","url":"https://stock-news.laohu8.com/highlight/detail?id=2482391783","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482391783?lang=zh_cn&edition=full","pubTime":"2024-11-11 20:19","pubTimestamp":1731327559,"startTime":"0","endTime":"0","summary":"2024年11月，在江西省药品监督管理局、江西省樟树药品监督管理局及江西省药品检验检测研究院的全力指导和帮助下，仁和药业历时7年研发的第一款经典名方产品”二冬汤颗粒“获批上市，仁和药业成为江西省首家获得经典名方批文的企业。什么是经典名方？根据《中华人民共和国中医药法》,古代经典名方是指“至今仍广泛运用、疗效确切、具有明显特色与优势的古代中医典籍所记载的方剂”。目前我国经典名方的开发明显滞后，其主要","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2024111100027071.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0188","000650","BK0239"],"gpt_icon":0},{"id":"2482274497","title":"仁和药业最新公告：子公司获得二冬汤颗粒药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2482274497","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482274497?lang=zh_cn&edition=full","pubTime":"2024-11-11 16:27","pubTimestamp":1731313671,"startTime":"0","endTime":"0","summary":"仁和药业公告，下属子公司江西药都樟树制药有限公司收到国家药监局核准签发的关于二冬汤颗粒的《药品注册证书》。该药品为中药3.1类，独家且为处方药。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111100020471.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0097","000650"],"gpt_icon":0},{"id":"2482275960","title":"仁和药业(000650.SZ)子公司获二冬汤颗粒药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2482275960","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482275960?lang=zh_cn&edition=full","pubTime":"2024-11-11 15:44","pubTimestamp":1731311091,"startTime":"0","endTime":"0","summary":"智通财经APP讯，仁和药业(000650.SZ)公告，公司下属子公司江西药都樟树制药有限公司收到国家药品监督管理局核准签发的关于二冬汤颗粒的《药品注册证书》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1209184.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0097","000650","BK0188","BK0239"],"gpt_icon":0},{"id":"2481422621","title":"仁和药业：子公司铝碳酸镁咀嚼片通过仿制药质量和疗效一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2481422621","media":"中国财富通","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481422621?lang=zh_cn&edition=full","pubTime":"2024-11-08 16:47","pubTimestamp":1731055623,"startTime":"0","endTime":"0","summary":"中国财富通11月8日 - 仁和药业（000650）公告称，近日，公司下属子公司江西药都仁和制药有限公司收到国家药品监督管理局核准签发的关于铝碳酸镁咀嚼片的《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。公司铝碳酸镁咀嚼片《药品补充申请批准通知书》的取得确保了该药品的正常生产和销售，有利于提升该药品的市场竞争力，同时为公司后续产品开展仿制药一致性评价工作积累了经验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=zlyQpnX4Tes%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0097","BK0188","000650"],"gpt_icon":0},{"id":"2481719102","title":"仁和药业(000650.SZ)：铝碳酸镁咀嚼片通过仿制药质量和疗效一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2481719102","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481719102?lang=zh_cn&edition=full","pubTime":"2024-11-08 11:58","pubTimestamp":1731038309,"startTime":"0","endTime":"0","summary":"智通财经APP讯，仁和药业(000650.SZ)公告，公司下属子公司江西药都仁和制药有限公司收到国家药品监督管理局(简称“国家药监局”)核准签发的关于铝碳酸镁咀嚼片的《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。据悉，铝碳酸镁咀嚼片为消化系统一线用药，具有抗酸、抗胆汁、保护粘膜的功效，三效合一整体治疗上消化道疾病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1208382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","000650","BK0097","BK0188"],"gpt_icon":0},{"id":"2481199465","title":"仁和药业：铝碳酸镁咀嚼片通过仿制药质量和疗效一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2481199465","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481199465?lang=zh_cn&edition=full","pubTime":"2024-11-08 11:53","pubTimestamp":1731038000,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0097","BK0188","000650","01477","BK1191","BK1574","BK0239"],"gpt_icon":0},{"id":"2480379965","title":"仁和药业(000650)10月31日股东户数11万户，较上期增加10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480379965","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480379965?lang=zh_cn&edition=full","pubTime":"2024-11-04 17:01","pubTimestamp":1730710878,"startTime":"0","endTime":"0","summary":"证券之星消息，近日仁和药业披露，截至2024年10月31日公司股东户数为11.0万户，较10月10日增加1.0万户，增幅为10.0%。在中药行业个股中，仁和药业股东户数高于行业平均水平，截至10月31日，中药行业平均股东户数为5.03万户。从股价来看，2024年10月10日至2024年10月31日，仁和药业区间跌幅为6.95%，在此期间股东户数增加1.0万户，增幅为10.0%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110400021990.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0097","BK0239","000650"],"gpt_icon":0},{"id":"2479694532","title":"仁和药业（000650）2024年三季报简析：净利润减23.08%，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2479694532","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479694532?lang=zh_cn&edition=full","pubTime":"2024-10-30 06:20","pubTimestamp":1730240413,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期仁和药业发布2024年三季报。截至本报告期末，公司营业总收入31.51亿元，同比下降17.49%，归母净利润4.16亿元，同比下降23.08%。按单季度数据看，第三季度营业总收入7.86亿元，同比下降30.83%，第三季度归母净利润7850.19万元，同比下降57.3%。本报告期仁和药业盈利能力上升，毛利率同比增幅5.15%，净利率同比增幅9.19%。去年的净利率为12.51%，算上全部成本后，公司产品或服务的附加值高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000006047.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650"],"gpt_icon":0},{"id":"2479420362","title":"仁和药业(000650)10月10日股东户数10万户，较上期减少2.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479420362","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479420362?lang=zh_cn&edition=full","pubTime":"2024-10-29 17:11","pubTimestamp":1730193114,"startTime":"0","endTime":"0","summary":"证券之星消息，近日仁和药业披露，截至2024年10月10日公司股东户数为10.0万户，较9月30日减少2612.0户，减幅为2.55%。在中药行业个股中，仁和药业股东户数高于行业平均水平，截至10月10日，中药行业平均股东户数为4.96万户。从股价来看，2024年9月30日至2024年10月10日，仁和药业区间跌幅为3.13%，在此期间股东户数减少2612.0户，减幅为2.55%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900030817.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0097","BK0239","000650"],"gpt_icon":0},{"id":"2478489557","title":"财报透视｜业绩双降！仁和药业三季度净利大幅下滑57.3%，销售费用是研发投入的15倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2478489557","media":"读创财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478489557?lang=zh_cn&edition=full","pubTime":"2024-10-28 20:43","pubTimestamp":1730119380,"startTime":"0","endTime":"0","summary":"归属于上市公司股东的净利润为7850万元，同比下降57.3%。仁和药业销售净利率和销售毛利率也整体下滑。今年半年报显示，仁和药业上半年营业收入为23.64亿元，同比下降11.84%；归属于上市公司股东的净利润为3.37亿元，同比下降5.43%；归属于上市公司股东的扣除非经常性损益的净利润为2.51亿元，同比下降19.29%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2024-10-28/doc-incucmqt9414472.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["000650"],"gpt_icon":0},{"id":"2478427170","title":"仁和药业(000650.SZ)发布前三季度业绩，净利润4.16亿元，同比下降23.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478427170","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478427170?lang=zh_cn&edition=full","pubTime":"2024-10-28 18:27","pubTimestamp":1730111279,"startTime":"0","endTime":"0","summary":"智通财经APP讯，仁和药业(000650.SZ)发布2024年三季度报告，前三季度，公司实现营业收入31.51亿元，同比下降17.49%。归属于上市公司股东的净利润4.16亿元，同比下降23.08%。归属于上市公司股东的扣除非经常性损益的净利润3.03亿元，同比下降35.13%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1201448.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000650"],"gpt_icon":0},{"id":"2478686174","title":"图解仁和药业三季报：第三季度单季净利润同比减57.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478686174","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478686174?lang=zh_cn&edition=full","pubTime":"2024-10-28 17:25","pubTimestamp":1730107547,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业2024年三季报显示，公司主营收入31.51亿元，同比下降17.49%；归母净利润4.16亿元，同比下降23.08%；扣非净利润3.03亿元，同比下降35.13%；其中2024年第三季度，公司单季度主营收入7.86亿元，同比下降30.83%；单季度归母净利润7850.19万元，同比下降57.3%；单季度扣非净利润5114.39万元，同比下降67.0%；负债率10.32%，投资收益2152.33万元，财务费用-981.65万元，毛利率37.65%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102800023666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650"],"gpt_icon":0},{"id":"2474216490","title":"10月9日仁和药业跌7.23%，广发稳健回报混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2474216490","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474216490?lang=zh_cn&edition=full","pubTime":"2024-10-09 17:13","pubTimestamp":1728465213,"startTime":"0","endTime":"0","summary":"证券之星消息，10月9日仁和药业跌7.23%，收盘报6.16元，换手率5.35%，成交量71.21万手，成交额4.49亿元。重仓仁和药业的前十大公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2024基金半年报公募基金重仓股数据，重仓该股的公募基金共20家，其中持有数量最多的公募基金为广发稳健回报混合A。广发稳健回报混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024100900030881.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","000650","BK0188","BK0239"],"gpt_icon":0},{"id":"2469465455","title":"仁和药业最新公告：全资子公司获得他达拉非片药品批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2469465455","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2469465455?lang=zh_cn&edition=full","pubTime":"2024-09-24 18:19","pubTimestamp":1727173165,"startTime":"0","endTime":"0","summary":"仁和药业公告，全资子公司江西药都仁和制药有限公司获得国家药品监督管理局核准签发的他达拉非片《药品补充申请批准通知书》。他达拉非是一种用于治疗勃起功能障碍的药物，公司此前已获得20mg规格的药品注册证书。此次新增5mg和10mg规格，累计研发投入约500万元。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092400029953.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0097","BK0188","000650"],"gpt_icon":0},{"id":"2466844801","title":"仁和药业（000650）9月10日主力资金净卖出532.67万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2466844801","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466844801?lang=zh_cn&edition=full","pubTime":"2024-09-11 09:26","pubTimestamp":1726017984,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年9月10日收盘，仁和药业报收于5.28元，下跌1.31%，换手率1.26%，成交量16.76万手，成交额8810.75万元。近5日资金流向一览见下表：仁和药业融资融券信息显示，融资方面，当日融资买入846.57万元，融资偿还992.83万元，融资净偿还146.26万元。仁和药业主营业务：生产、销售中西药、原料药及健康相关产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024091100009368.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0188","000650","BK0239"],"gpt_icon":0},{"id":"2463203307","title":"仁和药业：公司2023年12月至2024年3月已使用自有资金1亿元进行回购，本次回购已完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2463203307","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463203307?lang=zh_cn&edition=full","pubTime":"2024-08-31 16:00","pubTimestamp":1725091233,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业(000650)08月31日在投资者关系平台上答复投资者关心的问题。投资者：公司有27.74亿购买理财产品，为什么不用这些资金回购自己公司的股票呢，现在理财产品风险及高。仁和药业董秘：谢谢您的关注！公司2023年12月至2024年3月已使用自有资金1亿元进行回购，本次回购已完成。关于自有资金理财的情况，建议您查阅近三年公司披露的年度报告，报告里有详细的披露内容，同时您提到的建议公司证券部已反馈至公司决策管理层，谢谢！以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024083100012965.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0097","000650"],"gpt_icon":0},{"id":"2462556561","title":"仁和药业(000650)7月19日股东户数9.9万户，较上期增加1.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2462556561","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462556561?lang=zh_cn&edition=full","pubTime":"2024-08-27 17:05","pubTimestamp":1724749513,"startTime":"0","endTime":"0","summary":"证券之星消息，近日仁和药业披露，截至2024年7月19日公司股东户数为9.9万户，较7月10日增加1000.0户，增幅为1.02%。在中药行业个股中，仁和药业股东户数高于行业平均水平，截至7月19日，中药行业平均股东户数为5.03万户。从股价来看，2024年7月10日至2024年7月19日，仁和药业区间跌幅为0.0%，在此期间股东户数增加1000.0户，增幅为1.02%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082700029157.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650","BK0097","BK0188","BK0239"],"gpt_icon":0},{"id":"2462413070","title":"仁和药业最新公告：上半年净利润同比下降5.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2462413070","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462413070?lang=zh_cn&edition=full","pubTime":"2024-08-27 16:36","pubTimestamp":1724747802,"startTime":"0","endTime":"0","summary":"仁和药业发布2024年半年度报告，公司2024年上半年实现营业收入23.64亿元，同比下降11.84%；归属于上市公司股东的净利润3.37亿元，同比下降5.43%。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082700026867.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650"],"gpt_icon":0},{"id":"2462013470","title":"仁和药业(000650.SZ)发布上半年业绩，净利润3.37亿元，下降5.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2462013470","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462013470?lang=zh_cn&edition=full","pubTime":"2024-08-27 15:56","pubTimestamp":1724745370,"startTime":"0","endTime":"0","summary":"智通财经APP讯，仁和药业(000650.SZ)发布2024年半年度报告，报告期内，公司实现营业收入23.64亿元，同比下降11.84%。实现归属于上市公司股东的净利润3.37亿元，同比下降5.43%。实现归属于上市公司股东的扣除非经常性损益的净利润2.52亿元，同比下降19.29%。基本每股收益0.2409元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1171555.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000650"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1996-12-10","address":"江西省宜春市樟树市葛玄路6号","stockEarnings":[{"period":"1week","weight":-0.0133},{"period":"1month","weight":-0.0083},{"period":"3month","weight":0.129},{"period":"6month","weight":0.0464},{"period":"1year","weight":-0.0732},{"period":"ytd","weight":-0.0719}],"companyName":"仁和药业股份有限公司","boardCode":"AI0027","perCapita":"12103股","boardName":"医药制造业","registeredCapital":"139993万元","compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":0},{"period":"3month","weight":0.2307},{"period":"6month","weight":0.1234},{"period":"1year","weight":0.154},{"period":"ytd","weight":0.1321}],"survey":" 仁和药业股份有限公司主营业务是生产、销售中西药、原料药及健康相关产品。公司主营产品为口服固体制剂、口服液体制剂、大容量注射剂、小容量注射剂、外用洗剂、搽剂、栓剂、软膏剂等剂型药品以及健康相关产品。公司是全国通过GMP认证生产线最多的企业之一。","serverTime":1734964266798,"listedPrice":6.26,"stockholders":"110000人(较上一季度增加10.00%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"仁和药业(000650)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供仁和药业(000650)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"仁和药业,000650,仁和药业股票,仁和药业股票老虎,仁和药业股票老虎国际,仁和药业行情,仁和药业股票行情,仁和药业股价,仁和药业股市,仁和药业股票价格,仁和药业股票交易,仁和药业股票购买,仁和药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"仁和药业(000650)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供仁和药业(000650)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}